I. V. Sharutin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
I. V. Sharutin has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- A. N. Vorobiev
Peoples Friendship University of Russia (RUDN University)
1 shared publication - Anastasia Yurievna Efimenko
Lomonosov Moscow State University
1 shared publication - Anna O. Monakova
Lomonosov Moscow State University
1 shared publication - Arfenya Karamyan
RUDN University
1 shared publication - E. V. Elizarova
Peoples Friendship University of Russia (RUDN University)
1 shared publication - George D. Sagaradze
Medical Research and Educational Institute, Lomonosov Moscow State University
1 shared publication
Latest Publications
- Open Access
- 23 January 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (11) , 4561
Obtaining rat testicular cell cultures for research and development of biological drugs for spermatogenesis restoration
Aim . To create rat testicular cell collections characterized by phenotypes and functional activity to determine optimal conditions for their use in models for assessing the specific activity of spermatogenesis restoration drugs. Material and methods . To isolate different cell types from rat testes, sequential enzymatic treatment of testicular tissue was used. Immunocytochemical analysis of the isolated cell cultures was performed for canonical and non-canonical markers. Testosterone secretion by Leydig cells was measured on days 2, 4, and 7 of culture using enzyme-linked immunosorbent assay. The developed model for assessing the biological activity of drugs in Leydig cells was validated in accordance with the requirements of the Eurasian Economic Commission Decision dated July 17, 2018, № 113. Results. The following cell cultures were isolated from rat testes and characterized: Leydig cells expressing specific CYP11A1 and LHR markers; resident mesenchymal stromal/stem cells expressing CD73, CD90, and PDGFRb markers; Sertoli cells expressing inhibin beta B and Sox9 markers; spermatogonial stem cells expressing GDNFR, c-kit, and alkaline phosphatase markers; and peritubular myoid cells expressing αSMA. It was shown that Leydig cells, when isolated in culture, began expressing vinculin, and with prolonged cultivation and passaging, they acquired the Sox9 and vimentin markers. In addition, Leydig cells in culture sharply reduced their ability to secrete testosterone within a week. Based on these data, our previously developed in vitro model for assessing the specific activity of drugs for spermatogenesis restoration was optimized and validated. Conclusion . The approaches used enable the formation of characterized collections of different cell types isolated from the testes of laboratory animals. However, when isolated from tissue, due to the loss of a specific microenvironment, the phenotypic and functional properties of the cells may change over time in culture. This should be taken into account when creating and subsequently using cell collections. A study was conducted on the phenotype of testicular cells, as well as the secretory activity of Leydig cells. Based on this, a method for assessing specific activity in vitro and an optimal biobanking strategy were developed.
- 23 January 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (11) , 4561
Open AccessObtaining rat testicular cell cultures for research and development of biological drugs for spermatogenesis restoration
Aim . To create rat testicular cell collections characterized by phenotypes and functional activity to determine optimal conditions for their use in models for assessing the specific activity of spermatogenesis restoration drugs. Material and methods . To isolate different cell types from rat testes, sequential enzymatic treatment of testicular tissue was used. Immunocytochemical analysis of the isolated cell cultures was performed for canonical and non-canonical markers. Testosterone secretion by Leydig cells was measured on days 2, 4, and 7 of culture using enzyme-linked immunosorbent assay. The developed model for assessing the biological activity of drugs in Leydig cells was validated in accordance with the requirements of the Eurasian Economic Commission Decision dated July 17, 2018, № 113. Results. The following cell cultures were isolated from rat testes and characterized: Leydig cells expressing specific CYP11A1 and LHR markers; resident mesenchymal stromal/stem cells expressing CD73, CD90, and PDGFRb markers; Sertoli cells expressing inhibin beta B and Sox9 markers; spermatogonial stem cells expressing GDNFR, c-kit, and alkaline phosphatase markers; and peritubular myoid cells expressing αSMA. It was shown that Leydig cells, when isolated in culture, began expressing vinculin, and with prolonged cultivation and passaging, they acquired the Sox9 and vimentin markers. In addition, Leydig cells in culture sharply reduced their ability to secrete testosterone within a week. Based on these data, our previously developed in vitro model for assessing the specific activity of drugs for spermatogenesis restoration was optimized and validated. Conclusion . The approaches used enable the formation of characterized collections of different cell types isolated from the testes of laboratory animals. However, when isolated from tissue, due to the loss of a specific microenvironment, the phenotypic and functional properties of the cells may change over time in culture. This should be taken into account when creating and subsequently using cell collections. A study was conducted on the phenotype of testicular cells, as well as the secretory activity of Leydig cells. Based on this, a method for assessing specific activity in vitro and an optimal biobanking strategy were developed.
- Open Access
- 30 May 2022
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 11 (2) , 126-138
Development of Dihydroquercetin-based Oral tablets and Evalution of the General Toxic Effect
Разработка таблеток для приема внутрь на основе дигидрокверцетина и оценка их общетоксического действия
- 30 May 2022
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 11 (2) , 126-138
Open AccessDevelopment of Dihydroquercetin-based Oral tablets and Evalution of the General Toxic Effect
Разработка таблеток для приема внутрь на основе дигидрокверцетина и оценка их общетоксического действия